Rocket Pharmaceuticals, Inc.

DB:9IP1 Stock Report

Market Cap: €1.2b

Rocket Pharmaceuticals Valuation

Is 9IP1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9IP1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 9IP1 (€13.05) is trading below our estimate of fair value (€767.48)

Significantly Below Fair Value: 9IP1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9IP1?

Key metric: As 9IP1 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 9IP1. This is calculated by dividing 9IP1's market cap by their current book value.
What is 9IP1's PB Ratio?
PB Ratio3.9x
BookUS$329.77m
Market CapUS$1.29b

Price to Book Ratio vs Peers

How does 9IP1's PB Ratio compare to its peers?

The above table shows the PB ratio for 9IP1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
BIO3 Biotest
2x29.3%€1.3b
FYB Formycon
1.5x31.5%€857.2m
HPHA Heidelberg Pharma
3x-33.0%€105.8m
2INV 2invest
1xn/a€62.7m
9IP1 Rocket Pharmaceuticals
3.9x55.2%€1.3b

Price-To-Book vs Peers: 9IP1 is expensive based on its Price-To-Book Ratio (3.9x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does 9IP1's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
9IP1 3.9xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 9IP1 is expensive based on its Price-To-Book Ratio (3.9x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 9IP1's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9IP1 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 9IP1's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9IP1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€13.05
€44.16
+238.5%
21.5%€61.35€27.37n/a14
Nov ’25€14.93
€44.00
+194.8%
20.3%€60.22€28.72n/a14
Oct ’25€16.21
€43.16
+166.3%
21.0%€59.49€28.37n/a13
Sep ’25€16.57
€43.16
+160.4%
21.0%€59.49€28.37n/a13
Aug ’25€22.18
€43.45
+95.9%
19.4%€59.60€28.42n/a13
Jul ’25€19.10
€46.32
+142.5%
15.0%€60.68€34.54n/a13
Jun ’25€19.42
€46.42
+139.0%
14.3%€60.26€36.15n/a13
May ’25€20.26
€46.72
+130.6%
14.4%€60.37€36.22n/a13
Apr ’25€24.74
€47.29
+91.2%
13.1%€59.98€35.99n/a12
Mar ’25€27.00
€47.29
+75.2%
13.1%€59.98€35.99n/a12
Feb ’25€26.60
€47.02
+76.8%
14.3%€59.74€34.00n/a12
Jan ’25€27.93
€48.43
+73.4%
14.3%€60.83€34.63n/a12
Dec ’24€21.37
€48.43
+126.6%
14.3%€60.83€34.63n/a12
Nov ’24€17.90
€48.69
+172.0%
14.7%€60.96€36.57€14.9312
Oct ’24€19.48
€47.71
+144.9%
13.5%€60.57€36.34€16.2110
Sep ’24€14.43
€46.51
+222.4%
13.9%€55.72€35.63€16.5711
Aug ’24€16.37
€49.23
+200.7%
17.2%€68.03€35.38€22.1811
Jul ’24€18.61
€47.87
+157.2%
19.8%€68.17€31.81€19.1012
Jun ’24€19.30
€47.87
+148.1%
19.8%€68.17€31.81€19.4212
May ’24€15.99
€47.80
+198.9%
20.6%€68.06€29.95€20.2612
Apr ’24€14.73
€47.88
+225.1%
22.3%€70.91€31.20€24.7414
Mar ’24€19.64
€47.70
+142.9%
22.6%€70.34€30.95€27.0014
Feb ’24€19.83
€46.69
+135.5%
22.9%€68.27€30.04€26.6014
Jan ’24€18.00
€48.63
+170.3%
24.1%€70.77€31.14€27.9313
Dec ’23€17.17
€50.58
+194.7%
22.7%€72.11€31.73€21.3713
Nov ’23€19.04
€54.50
+186.3%
22.9%€75.93€34.42€17.9012

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.65

7D

-3.7%

1Y

76.2%

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.60

7D

5.7%

1Y

27.6%

Pharming Group

€491.5m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.70

7D

-0.7%

1Y

-34.1%